Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845226 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL13272444 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL1030175 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL15116912 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL845111 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL845160 | 0.96 | HSD11B1 (0.53) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL845171 | 0.96 | ALDH1A1 (0.53) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL845408 | 0.95 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL845154 | 0.95 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAITGB1ITGA4 | |
| SCHEMBL845406 | 0.95 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2274281-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2015-05-27 | — | — | EP | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-8143288-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143288-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110178107-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-07-21 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
| EP-2274281-A1 | HCV PROTEASE INHIBITORS | Taigen Biotechnology Co., Ltd. (TW) | 2011-01-19 | — | — | EP | disclosed |
| EP-1893573-B1 | INHIBITORS OF HCV REPLICATION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
| WO-2009139792-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | RNASE1, HAVCR2, CTRL | ALDH1A1 814/4885KDM4E 1513/4885LMNA 4510/4885 |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | HAVCR2, SPINT2, RNASE1 | ALDH1A1 982/4885KDM4E 1896/4885LMNA 4532/4885 |
| US-20110178107-A1 | HCV PROTEASE INHIBITORS | HAVCR2, RNASE1, SERPINB1 | ALDH1A1 714/4885KDM4E 2187/4885LMNA 4575/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 3966/4885KDM4E 3572/4885LMNA 4392/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 3966/4885KDM4E 3572/4885LMNA 4392/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | ALDH1A1 3966/4885KDM4E 3572/4885LMNA 4392/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ALDH1A1 3872/4885KDM4E 3714/4885LMNA 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.